Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa

Cystic Fibrosis Clinical Trial

— AIR-CF4  

Official title:

A Double-Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreonam Lysine For Inhalation in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa (AIR-CF4)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00712166
• Other study ID #: GS-US-205-0117
• Status: Completed
• Phase: Phase 3
• First received: July 7, 2008
• Last updated: November 19, 2010
• Start date: May 2008
• Est. completion date: August 2009

Study information

• Verified date: November 2010
• Source: Gilead Sciences
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study was to evaluate the safety and efficacy of a 28-day course of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF), mild lung disease (forced expiratory volume in 1 second [FEV1] >75% predicted, and Pseudomonas aeruginosa (PA) infection.

Description:

CF patients often have lung infections that occur repeatedly or worsen over time. The lung infections are often caused by a bacteria called Pseudomonas aeruginosa (PA). Treatment with antibiotics can stop or slow down the growth of the bacteria. The antibiotics may be given by mouth, intravenously (IV), or by inhalation as a mist. The purpose of this study was to evaluate the safety and efficacy of AZLI, an investigational formulation of the antibiotic aztreonam and administered three times a day using the PARI eFlow® electronic nebulizer, in CF patients with PA and mild lung disease.

In this study, participant eligibility was assessed at a screening visit that occurred up to 14 days prior to the baseline visit (Day 0). Those participants who met eligibility criteria at Day 0 were randomized and began a 28-day course of blinded study treatment (AZLI or placebo TID). Participants returned for clinic visits at Day 14, an end of treatment visit at Day 28, and a follow up visit 14 days after the last dose of the trial drug (Day 42).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 160
• Est. completion date: August 2009
• Est. primary completion date: June 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 6 Years and older

Eligibility

Inclusion Criteria:

• Participants = 6 years of age

• Documentation of CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:

• Sweat chloride = 60 mEq/L by quantitative pilocarpine iontophoresis test

• Two well characterized mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene

• Abnormal nasal potential difference

• PA present in expectorated sputum or throat swab culture at Visit 1 OR documented PA in 2 expectorated sputum or throat swab cultures within the 12 months prior to Visit 1 (one of the previous PA positive cultures must have been no more than 3 months prior to Visit 1)

• FEV1 > 75% predicted at Visit 1

• Participants must have exhibited two or more of the following chronic and/or intermittent CF symptoms, for a minimum of 28 days prior to randomization and with no worsening of symptoms within 7 days prior to randomization:

• Chest congestion

• Daily cough

• Productive cough

• Wheezing

• Trouble breathing

• Nocturnal wakening due to coughing

• Participants (and parent/guardian as required) had to be able to provide written informed consent/assent prior to any study related procedures

• Females of childbearing potential had to have a negative urine pregnancy test at Visit 1

• Ability to perform reproducible pulmonary function tests

• In the opinion of the Investigator, the participant did not require immediate antipseudomonal antibiotic intervention to treat an impending exacerbation, and the participant's condition was stable enough to enroll in the study

Exclusion Criteria:

• Administration of any investigational drug or device within 28 days prior to Visit 1 or within 6 half-lives of the investigational drug (whichever was longer)

• Administration of any IV, oral, or inhaled antipseudomonal antibiotic within 28 days prior to Visit 1

• Known local or systemic hypersensitivity to monobactam antibiotics

• Inability to tolerate short-acting bronchodilator (BD) use at least TID

• Changes in or initiation of chronic azithromycin treatment within 28 days prior to Visit 1

• Changes in or initiation of chronic hypertonic saline treatment within 28 days prior to Visit 1

• Changes in or initiation of dornase alfa within 28 days prior to Visit 1

• Changes in antimicrobial, BD, or corticosteroid medications within 7 days prior to Visit 1

• Changes in physiotherapy technique or schedule within 7 days prior to Visit 1

• History of lung transplantation

• History of participation (enrollment) in any prior clinical studies with AZLI

• A chest radiograph at Visit 1 (or within the previous 180 days of Visit 1), with abnormalities indicating a significant acute finding (e.g., lobar infiltrate and atelectasis, pneumothorax, or pleural effusion); a chest radiograph obtained and interpreted between Visits 1 and 2 was also acceptable for determining eligibility

• Positive urine pregnancy test at Visit 1; all women of childbearing potential were to be tested

• Females of childbearing potential who were lactating or were not (in the opinion of the investigator) practicing an acceptable method of birth control; female participants who utilized hormonal contraceptives as their birth control method must have used the same method for at least 3 months before study dosing

• Participant was being assessed at Visit 1 by the investigator for an acute change in respiratory symptoms

• Any serious or active medical or psychiatric illness, which in the opinion of the investigator, would have interfered with participant treatment, assessment, or compliance with the protocol

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cystic Fibrosis
• Fibrosis
• Lung Diseases
• Lung Infection
• Pseudomonas Aeruginosa
• Pseudomonas Infections

Intervention

Drug:
• AZLI 75 mg three times daily (TID)

• Placebo three times daily (TID)

Locations

Country	Name	City	State
Australia	The Prince Charles Hospital, Adult Cystic Fibrosis Centre	Chermside	Queensland
Australia	Respiratory Medicine, Royal Children's Hospital	Herston	Queensland
Australia	Child and Adolescent Health Services, Princess Margaret Hospital	Perth	Western Australia
Australia	Department of Respiratory Medicine, The Children's Hospital at Westmead	Westmead	New South Wales
Australia	Department of Respiratory Medicine, Westmead Hospital	Westmead	New South Wales
Canada	Centre de Recherche du CHUM	Montreal	Quebec
United States	Albany Medical College	Albany	New York
United States	University of Michigan Health System	Ann Arbor	Michigan
United States	The Children's Hospital	Aurora	Colorado
United States	Children's Hospital, Boston	Boston	Massachusetts
United States	Tufts Medical Center, Pediatric Pulmonary Clinic	Boston	Massachusetts
United States	The Lung & Cystic Fibrosis Center, University of Buffalo Pediatric Associates, Inc., Women & Children's Hospital of Buffalo	Buffalo	New York
United States	Children's Memorial Hospital	Chicago	Illinois
United States	Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio
United States	Nationwide Children's Hospital	Columbus	Ohio
United States	The Children's Hospital of Michigan, Detroit Medical Center	Detroit	Michigan
United States	Connecticut Children's Medical Center	Hartford	Connecticut
United States	Penn State Milton S. Hershey Medical Center	Hershey	Pennsylvania
United States	Baylor College of Medicine	Houston	Texas
United States	Indiana University, Outpatient Clinical Research Facility	Indianapolis	Indiana
United States	James Whitcomb Riley Hospital for Children	Indianapolis	Indiana
United States	Nemours Children's Clinic	Jacksonville	Florida
United States	Children's Lung Specialists	Las Vegas	Nevada
United States	Arkansas Children's Hospital	Little Rock	Arkansas
United States	University of Arkansas for Medical Sciences, Division of Pulmonary and Critical Care Medicine	Little Rock	Arkansas
United States	The Minnesota CF Center, University of Minnesota Medical Center	Minneapolis	Minnesota
United States	Long Island Jewish Medical Center	New Hyde Park	New York
United States	Kaiser Permanente	Oakland	California
United States	Santiago Reyes, MD	Oklahoma City	Oklahoma
United States	Children's Hospital of Orange County	Orange	California
United States	Nemours Children's Clinic	Orlando	Florida
United States	Drexel University College of Medicine, Pulmonary Associates	Philadelphia	Pennsylvania
United States	Penn Presbyterian Medical Center	Philadelphia	Pennsylvania
United States	St. Christopher's Hospital for Children	Philadelphia	Pennsylvania
United States	Phoenix Children's Hospital	Phoenix	Arizona
United States	Primary Children's Medical Center	Salt Lake City	Utah
United States	Children's Hospital and Regional Medical Center	Seattle	Washington
United States	SUNY Upstate Medical University	Syracuse	New York
United States	Toledo Children's Hospital/Toledo Hospital, Cystic Fibrosis Research Center	Toledo	Ohio
United States	University Medical Center	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Gilead Sciences

Countries where clinical trial is conducted

United States,  Australia,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Cystic Fibrosis Questionnaire - Revised (CFQ-R) Respiratory Symptoms Scale (RSS) Score at Day 28	The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for children and adults with CF. The CFQ-R contains both general and CF-specific scales. The CFQ-R was administered at Days 0, 14, 28, and 42. The endpoint was change in respiratory symptoms (e.g., coughing, congestion, wheezing) from Day 0 (baseline), assessed with the CFQ-R RSS (score range: 0-100; higher scores indicating fewer symptoms, higher health-related quality of life, or better functioning). Baseline CFQ-R RSS and age group (<18 vs. >=18 years) were included as covariates in the analysis.	Day 0 to Day 28	No
Secondary	Change From Baseline in CFQ-R RSS Score at Day 14	The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for children and adults with CF. The CFQ-R contains both general and CF-specific scales. The CFQ-R was administered at Days 0, 14, 28, and 42. The endpoint was change in respiratory symptoms (e.g., coughing, congestion, wheezing) from Day 0 (baseline), assessed with the CFQ-R RSS (score range: 0-100; higher scores indicating fewer symptoms, higher health-related quality of life, or better functioning). Baseline CFQ-R RSS and age group (<18 vs. >=18 years) were included as covariates in the analysis.	Day 0 to Day 14	No
Secondary	Change From Baseline in CFQ-R RSS Score at Day 42	The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for children and adults with CF. The CFQ-R contains both general and CF-specific scales. The CFQ-R was administered at Days 0, 14, 28, and 42. The endpoint was change in respiratory symptoms (e.g., coughing, congestion, wheezing) from Day 0 (baseline), assessed with the CFQ-R RSS (score range: 0-100; higher scores indicating fewer symptoms, higher health-related quality of life, or better functioning). Baseline CFQ-R RSS and age group (<18 vs. >=18 years) were included as covariates in the analysis.	Day 0 to Day 42	No
Secondary	Change From Baseline in CFQ-R Physical Functioning Domain Score	The CFQ-R contains both general and CF-specific scales. The CFQ-R was administered at Days 0 (baseline), 14, 28, and 42 (the last study visit). The endpoint was change from baseline in the physical functioning domain (e.g., ability to walk and engage in physical activities) of the CFQ-R at Day 28 (range of scores: 0-100; higher scores indicating fewer symptoms, higher health-related quality of life, or better functioning). Baseline CFQ-R physical functioning domain score and age group (<18 vs. >=18 years) were included as covariates in the analysis.	Day 0 to Day 28	No
Secondary	Number of Participants Using Additional (Nonprotocol-specified) Antipseudomonal Antibiotics During Study	The number of participants requiring additional antipseudomonal antibiotics (oral, intravenous [IV], or by inhalation), the time to use of these antibiotics, and the reasons for use was recorded. A binary variable was defined to indicate whether the participants needed any antipseudomonal antibiotics that were non-study drug via the oral, IV, or inhalation route between Day 0 (Baseline Visit) and Day 42 (Visit 5). Fisher's Exact Test was implemented on the intent-to-treat (ITT) and per protocol analysis sets to detect treatment effects on need for additional antipseudomonal antibiotics.	Day 0 to Day 42	No
Secondary	Number of Participants Hospitalized During Study	Hospitalization was defined as any hospital admission lasting for more than 1 calendar day that had been recorded as a serious adverse event (SAE) on the electronic case report form (eCRF). Binary variables were defined to indicate whether participants experienced any hospitalization. Number of hospitalizations was summarized by treatment group.	Day 0 to Day 42	No
Secondary	Change From Baseline in Log10 Pseudomonas Aeruginosa (PA) Colony Forming Units (CFUs) in Sputum at Day 28	Sputum samples were collected at all study visits for quantitative and qualitative culture for PA. Sputum PA density was quantified by logarithm transformation of the CFU value with base 10. Change from baseline in sputum PA density was calculated as the difference between the log10 CFU values at Day 28 (Visit 4) and the baseline value. Missing data was not imputed. Baseline log10 CFU and age group (<18 vs. >=18 years) were included as covariates in the analysis.	Day 0 to Day 28	No
Secondary	Relative Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted	Spirometry was performed according to American Thoracic Society (ATS) guidelines at each visit. Treatment effect on the relative change from baseline in FEV1 percent predicted at Day 28 (Visit 4) was tested by the ANCOVA model using the ITT analysis set. Baseline FEV1 percent predicted and age group (<18 vs. >=18 years) were included as covariates in the analysis.	Day 0 to Day 28	No